Effects of Angiotensin II-Receptor Blockade with Losartan on Insulin Sensitivity, Lipid Profile, and Endothelin in Normotensive Offspring of Hypertensive Parents
Authors:
- M. LerchMLM. Lerch
- A. U. TeuscherATA. U. Teuscher
- P. BeissnerPBP. Beissner
- M. SchneiderMSM. Schneider
- S. G. ShawSSS. G. Shaw
- P. WeidmannPWP. Weidmann
- 1 April 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 31 (4) , 576-580
Abstract
Humans genetically predisposed to hypertension tend to develop at a prehypertensive stage subtle metabolic and hormonal dysregulations, and certain of these could potentially be angiotensin II dependent. Therefore the aim of this study was to investigate the effects of the angiotensin II-receptor antagonist losartan on insulin sensitivity, lipid profile, and plasma endothelin-1 (ET-1) levels in normotensive offspring of hypertensive parents with a randomized, double-blind, placebo- controlled, crossover design. Insulin sensitivity index (SI), determined by the Minimal Model Method of Bergman, fasting plasma insulin and glucose concentrations, serum total and HDL cholesterol, serum triglycerides, and plasma ET-1 levels were assessed in 19 young (26.2 ± 0.7 years, mean ± SEM), healthy, lean [body mass index (BMI), 22.6 ± 0.7 kg/m2] normotensive male offspring of essential hypertensive parents after 14 days of losartan, 50 mg, and 14 days of placebo, respectively. Compared with placebo, losartan administration did not significantly modify SI (12.2 ± 1.7 vs. 12.7 ± 1.5 × 10−4/min/μU/ml on placebo), fasting plasma insulin and glucose, as well as the areas under the insulin and glucose curves. Plasma ET-1 levels also did not differ significantly between the placebo and losartan administration phases (1.1 ± 0.06 vs. 1.2 ± 0.06 pg/ml). However, serum total cholesterol and triglycerides decreased significantly with losartan treatment (3.8 ± 0.2 vs. 4.1 ± 0.2 mM and 0.9 ± 0.1 vs. 1.1 ± 0.1 mM, respectively; p < 0.01). Body weight, BMI, heart rate (HR), blood pressure (BP), and 24-h urinary sodium, potassium, and creatinine values were stable throughout the study. These findings demonstrate that angiotensin II-receptor blockade with losartan, administered in the therapeutic dose of 50 mg daily, does not alter insulin sensitivity determined by the Minimal Model Method of Bergman and does not affect ET-1 in normotensive offspring of essential hypertensive parents. The normal insulin sensitivity in the subjects studied might explain why losartan did not improve it. However, losartan significantly reduced serum total cholesterol and total triglyceride levels.Keywords
This publication has 37 references indexed in Scilit:
- Increased Activation of Sympathetic Nervous System and Endothelin by Mental Stress in Normotensive Offspring of Hypertensive ParentsCirculation, 1996
- Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parentsThe Lancet, 1993
- Insulin Resistance, Hyperinsulinemia, and Dyslipidemia in Nonobese Individuals With a Family History of HypertensionAmerican Journal of Hypertension, 1992
- Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parentThe American Journal of Medicine, 1991
- Renal Hemodynamics and the Renin–Angiotensin–Aldosterone System in Normotensive Subjects with Hypertensive and Normotensive ParentsNew England Journal of Medicine, 1991
- Dysregulation of Atrial Natriuretic Factor in Hypertension-Prone Man*The Journal of Clinical Endocrinology & Metabolism, 1990
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988
- Insulin Resistance in Essential HypertensionNew England Journal of Medicine, 1987
- Potassium and norepinephrine- or angiotensin–mediated pressor control in pre-hypertensionKidney International, 1987
- Red-Cell Lithium-Sodium Countertransport and Renal Lithium Clearance in HypertensionNew England Journal of Medicine, 1986